Enovis Corp

Enovis insider sales show routine portfolio moves, not a confidence shift; meanwhile, its EPDS device gains FDA clearance and promising phase‑III results, hinting at future market impact.

Enovis insider buying signals confidence in its anti‑IL‑23 drug & diagnostic assays, despite negative earnings—potential game‑changer for psoriasis and rheumatoid arthritis care.